Skip to main content
. 2021 Sep 3;12:720354. doi: 10.3389/fimmu.2021.720354

Figure 1.

Figure 1

Comparison of the frequency and number of mucosa-associated invariant T (MAIT) cells in the grafts from the recombinant human granulocyte colony-stimulating factor (rhG-CSF) mobilized donors and healthy person. (A) Flow cytometry of MAIT cells in the grafts of four patient groups. (B) The frequency of MAIT cells (% of CD3+ cells) in graft-bone marrow (BM) [Healthy, n = 4; No acute graft-versus-host disease (aGVHD), n = 21; Skin aGVHD, n = 28; Gut aGVHD, n = 12] and graft-peripheral blood (PB) (Healthy, n = 8; No aGVHD, n = 24; Skin aGVHD, n = 27; Gut aGVHD, n = 15; Gut aGVHD vs. Healthy, p = 0.029). (C) The number of MAIT cells in graft-BM, graft-PB (Gut aGVHD vs. no aGVHD, p = 0.028; Skin aGVHD vs. no aGVHD, p = 0.042), and the total grafts (No aGVHD, n = 16; Skin aGVHD, n = 13; Gut aGVHD, n = 13). (D) The influence of the high MAIT (>5.3 × 106/kg) and low MAIT (<5.3 × 106/kg) group level in the graft on the occurrence of aGVHD (I aGVHD and II–IV aGVHD). (E) The influence of the high MAIT (>5.3 × 106/kg) and low MAIT (<5.3×106/kg) groups in infused graft on gut aGVHD (p = 0.018) or skin aGVHD. (F) The influence of the high MAIT (>5.3 × 106/kg) and low MAIT (<5.3 × 106/kg) groups in infused graft on the prognosis after transplantation. Levels of significances are given as p-values with **≤0.05 and *≤0.1.